The threat of a major human influenza pandemic such as
the avian H5N1 or the 2009 new H1N1 has emphasized the
need for effective prevention strategies to combat these pathogens.
Although egg based influenza vaccines have been well
established for a long time, it remains an ongoing public
health need to develop alternative production methods that
ensures improved safety, efficacy, and ease of administration
compared with conventional influenza vaccines. This article
is intended to cover some of the recent advances and related
patents on the development of influenza vaccines including
live attenuated, cell based, genomic and synthetic peptide
vaccines.
Citations
Citations to this article as recorded by
Plant-made virus-like particles bearing influenza hemagglutinin (HA) recapitulate early interactions of native influenza virions with human monocytes/macrophages Alexander I. Makarkov, Sabrina Chierzi, Stéphane Pillet, Keith K. Murai, Nathalie Landry, Brian J. Ward Vaccine.2017; 35(35): 4629. CrossRef